
Opinion|Videos|January 24, 2025
Understanding CRS and ICANS: Real-World Incidence and Key Patient Risk Factors
Panelists discuss how real-world data on the incidence of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) compare with clinical trial findings as well as the most critical patient-related risk factors for developing these toxicities.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do real-world data on the incidence of CRS and ICANS compare with clinical trial findings? (Dr Allan )
- What are the most critical patient-related risk factors for CRS and ICANS? (Dr Graff)
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Mirvetuximab Soravtansine Demonstrates Promising Efficacy, Safety in Platinum-Resistant Recurrent Ovarian Cancer
2
How Artificial Intelligence Is Transforming Leukemia Detection and Diagnosis
3
Long-Term Remission in Ph-Negative B-ALL With Sequential CAR T, ASCT
4
5 Ways ACOs Can Improve Care, Achieve Meaningful Savings
5












































